Literature DB >> 8258510

Motion perception in glaucoma.

M A Bullimore1, J M Wood, K Swenson.   

Abstract

PURPOSE: This study was performed to investigate motion perception in patients with glaucoma.
METHODS: A random dot motion test was used to measure three aspects of central motion perception: minimum displacement threshold (Dmin), maximum displacement threshold (Dmax), and coherence threshold (signal to noise). Motion perception was assessed in 15 patients with primary open-angle glaucoma, 23 low-risk patients in whom glaucoma was suspected, and 24 age-matched normal subjects.
RESULTS: Central motion perception was significantly impaired in patients with glaucoma; in particular, the Dmin was nearly twice that for the normal subjects (glaucoma mean, -0.27 +/- 0.24 log minutes of arc; normal mean, -0.56 +/- 0.13 log minutes of arc; F = 21.79, P < 0.001). Furthermore, Dmin values fell outside the normal range in 10 of the 15 patients with glaucoma, despite normal visual acuity and normal foveal perimetric thresholds. Coherence thresholds and Dmax did not discriminate between patients with glaucoma and normal subjects. Dmin was not correlated with any indices of perimetric sensitivity, and none of the tests of motion perception showed any abnormalities in patients in whom glaucoma was suspected.
CONCLUSIONS: Central motion perception can be affected in glaucoma and may reflect preferential damage to larger retinal ganglion cells. Future work will measure Dmin in a larger population of patients with suspected glaucoma and those with glaucoma, and investigate peripheral motion perception in glaucoma.

Entities:  

Mesh:

Year:  1993        PMID: 8258510

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  9 in total

1.  Temporal contrast sensitivity with peripheral and central stimulation in glaucoma diagnosis.

Authors:  I M Velten; M Korth; F K Horn; W M Budde
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

2.  Motion discrimination of single targets: comparison of preliminary findings in normal subjects and patients with glaucoma.

Authors:  A Sahraie; J L Barbur; D F Edgar; L Weiskrantz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

3.  Pattern electroretinogram and peripheral colour contrast thresholds in ocular hypertension and glaucoma: comparison and correlation of results.

Authors:  S T Ruben; G B Arden; F O'Sullivan; R A Hitchings
Journal:  Br J Ophthalmol       Date:  1995-04       Impact factor: 4.638

4.  Rapid Campimetry-A Novel Screening Method for Glaucoma Diagnosis.

Authors:  Fabian Müller; Khaldoon O Al-Nosairy; Francie H Kramer; Christian Meltendorf; Nidele Djouoma; Hagen Thieme; Michael B Hoffmann; Friedrich Hoffmann
Journal:  J Clin Med       Date:  2022-04-12       Impact factor: 4.964

5.  Assessment of Driving Safety in Older Adults with Mild Cognitive Impairment.

Authors:  Kaarin J Anstey; Ranmalee Eramudugolla; Sidhant Chopra; Jasmine Price; Joanne M Wood
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

6.  Differential aging effects in motion perception tasks for central and peripheral vision.

Authors:  Juan A Sepulveda; Andrew J Anderson; Joanne M Wood; Allison M McKendrick
Journal:  J Vis       Date:  2020-05-11       Impact factor: 2.240

7.  Vision Impairment Provides New Insight Into Self-Motion Perception.

Authors:  Wilson Luu; Barbara Zangerl; Michael Kalloniatis; Stephen Palmisano; Juno Kim
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-02-01       Impact factor: 4.799

8.  Hazard Perception in Older Drivers With Eye Disease.

Authors:  Joanne M Wood; Alex A Black; Kaarin J Anstey; Mark S Horswill
Journal:  Transl Vis Sci Technol       Date:  2021-01-22       Impact factor: 3.283

9.  Visual Predictors of Postural Sway in Older Adults.

Authors:  Joanne M Wood; Callula Killingly; David B Elliott; Kaarin J Anstey; Alex A Black
Journal:  Transl Vis Sci Technol       Date:  2022-08-01       Impact factor: 3.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.